Statement of Changes in Beneficial Ownership (4)
September 08 2020 - 07:08PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * RAVICH
MARK H |
2. Issuer Name and Ticker or Trading
Symbol ROCKWELL MEDICAL, INC. [ RMTI ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)__X__
Director _____
10% Owner
_____ Officer (give title
below) _____ Other
(specify below)
|
(Last)
(First)
(Middle)
C/O ROCKWELL MEDICAL, INC., 411 HACKENSACK AVENUE, SUITE
501 |
3. Date of Earliest Transaction (MM/DD/YYYY)
9/3/2020
|
(Street)
HACKENSACK, NJ 07601
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
Amount |
(A) or (D) |
Price |
Common Stock |
9/3/2020 |
|
J(1) |
|
173905 |
D |
$1.21 (2) |
213604 (3) |
D |
|
Common Stock |
9/3/2020 |
|
J(1) |
|
11000 (4) |
D |
$1.21 |
0 |
I |
By: Norman and Sally Ravich Family
Trust (5) |
Common Stock |
9/3/2020 |
|
J(1) |
|
194905 |
A |
$1.22 (6) |
194905 |
I |
By: Cindy Libman Irrevocable
Trust (7) |
Common Stock |
9/4/2020 |
|
J(1) |
|
10000 |
D |
$1.16 |
203604 (3) |
D |
|
Common Stock |
9/4/2020 |
|
J(1) |
|
16000 |
D |
$1.16 |
9000 |
I |
By: Alexander Coleman Ravich 1991 Irrevocable
Trust (8) |
Common Stock |
9/4/2020 |
|
J(1) |
|
9000 |
D |
$1.16 |
16000 |
I |
By: Alyssa Danielle Ravich 1991 Irrevocable
Trust (9) |
Common Stock |
9/4/2020 |
|
J(1) |
|
25000 |
A |
$1.22 (10) |
219905 |
I |
By: Cindy Libman Irrevocable
Trust (7) |
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Explanation of
Responses: |
(1) |
Represents the transfer of
shares of common stock to Cindy Libman Irrevocable Trust ("CL
Trust") for which the Reporting Person is the trustee. The
Reporting Person's total beneficial ownership in the Issuer has not
changed, as he was the beneficial owner of these shares both before
and after the transfers reported herein. |
(2) |
The price reported in Column
4 is a weighted average price. These shares were sold in multiple
transactions at prices ranging from $1.21 to $1.22 inclusive. The
Reporting Person undertakes to provide to the Issuer, any
securityholder of the Issuer, or the staff of the Securities and
Exchange Commission, upon request, full information regarding the
number of shares purchased at each price within the
range. |
(3) |
Includes 30,000 shares of
common stock underlying unvested restricted stock units that vest
based on the achievement of certain time-based
milestones. |
(4) |
Includes 1,000 shares which
were inadvertently omitted in previous filings due to
administrative error. |
(5) |
Represents securities owned
directly by Norman and Sally Ravich Family Trust ("NSR Trust"). Mr.
Ravich, as the trustee of NSR Trust, may be deemed to beneficially
own the securities owned directly by NSR Trust. |
(6) |
The price reported in Column
4 is a weighted average price. These shares were purchased in
multiple transactions at prices ranging from $1.20 to $1.23
inclusive. The Reporting Person undertakes to provide to the
Issuer, any securityholder of the Issuer, or the staff of the
Securities and Exchange Commission, upon request, full information
regarding the number of shares purchased at each price within the
range. |
(7) |
Represents securities owned
directly by CL Trust. Mr. Ravich, as the trustee of CL Trust, may
be deemed to beneficially own the securities owned directly by CL
Trust. |
(8) |
Represents securities owned
directly by Alexander Coleman Ravich 1991 Irrevocable Trust ("ACR
Trust"). Mr. Ravich, as the trustee of ACR Trust, may be deemed to
beneficially own the securities owned directly by ACR
Trust. |
(9) |
Represents securities owned
directly by Alyssa Danielle Ravich 1991 Irrevocable Trust ("ADR
Trust"). Mr. Ravich, as the trustee of ADR Trust, may be deemed to
beneficially own the securities owned directly by ADR
Trust. |
(10) |
The price reported in Column
4 is a weighted average price. These shares were purchased in
multiple transactions at prices ranging from $1.21 to $1.22
inclusive. The Reporting Person undertakes to provide to the
Issuer, any securityholder of the Issuer, or the staff of the
Securities and Exchange Commission, upon request, full information
regarding the number of shares purchased at each price within the
range. |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
RAVICH MARK H
C/O ROCKWELL MEDICAL, INC.
411 HACKENSACK AVENUE, SUITE 501
HACKENSACK, NJ 07601 |
X |
|
|
|
Signatures
|
/s/ Michael G. Costello, Attorney-in-Fact for
Mark H. Ravich |
|
9/8/2020 |
**Signature of
Reporting Person |
Date |